Právní předpis byl sestaven k datu 22.11.2026.
Zobrazené znění právního předpisu je účinné od 15.09.2026.
Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
163/2026 Sb.
163
SDĚLENÍ
Ministerstva xxxxxxxxxxxx věcí,
kterým xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. x č. 46/2008 Xx. x. x.
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 15. listopadu 2024 xxxx generální ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Seznam xxxxxxxxxx xxxxx x xxxxx xxxxxxx pro xxx 2025 - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx.
X xxxxx xxxxxx Přílohy I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Přílohy I Xxxxxx republikou.
Nové xxxxx Přílohy I xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 odst. 3 Úmluvy xxx 1. xxxxx 2025, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 15. září 2025 x nahradilo Přílohu I xxx xxx 2024, platnou xx 1. xxxxx 2024, xxxxx xxxxxxxxx x xxxxxxxx xxx Českou xxxxxxxxx xxx 18. xxxxxx 2024 a xxxx xxxxxxxxx xxx č. 19/2025 Sb.
Xxxxxxxx znění Přílohy I xxx xxx 2025 x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
Xxxxxxx:
x x. Xxx. Šlais x. x.
xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;
Xxxx
Xxxxxx zakázaných xxxxx x metod je xxxxxxx Mezinárodní standard x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (WADA). Xxxxxx xx xxxxxx xx 1. xxxxx 2025.
Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx XXXX x bude xxxxxxxxxx x angličtině x xxxxxxxxxxxxx. V xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským xxxxxx rozhoduje xxxxx x angličtině.
Níže xxxx xxxxxxx xxxxxxx pojmy xxxxxxxxx v tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx WADA pro xxxx xxxxx neschválila xxxx období, je xxxxxx Při xxxxxxx x zásadě xxxxxxx xxxxxxxxxxx těsně xxxx xxxxxxx (xx 23:59 xxxxx) v xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, až xx xxxxx Xxxxxxx a xxxxxxx xxxxxx Vzorku.
Zakázané xxxxx
Xx znamená, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx soutěž, jak xx xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Kodexu „pro xxxxx aplikace článku 10 xxxxx všechny Xxxxxxxx xxxxx Specifickými xxxxxxx, s xxxxxxxx xxxx xxxxxxxxxx x Xxxxxxx zakázaných xxxxx x xxxxx. Xxxxx Xxxxxxxx metoda nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Seznamu xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda“. Xxxxx xxxxxxxxx k článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx považovány xx xxxx důležité xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx nebo xxxxxx. Xxx xxxxx x xxxxx a xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx použil x xxxxxx xxxxx xxx ke zlepšení xxxxxxxxxxx xxxxxx.“
Xxxxxxxx látky
Podle xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou jako xxxxxx xxxxxxxx x xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve společnosti xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx xxxx xxxxx: kokain, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané látky x xxxx třídě xxxx Specifické látky.
Jakákoliv xxxxxxxxxxxxxx látka, xx xxxxxx xx xxxxxxxxxx xxxxx z xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx xxxx v xxxxxxxx době xxxxxxxxx xxxxxx vládním zdravotnickým xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x předklinickém nebo xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj byl xxxxxxx, značková xxxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx xxxx zakázána.
Tato xxxxx zahrnuje mnoho xxxxxxx látek, xxxx xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX), stabilizátory xxxxxxxx xxxxxxxxxxxxx xxxxxxxxx-1-xxxxxxxxxx [např. X-107, S48168 (XXX210)] x aktivátory xxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.
Anabolické látky xxxx xxxxxxxx.
X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx xxxx včetně:
|
• |
1-androstenediol (5ɑ -xxxxxxx-1-xx-3ß, 17ß-xxxx) |
• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (5ɑ -xxxxxxx-1-xx-3, 17-xxxx) |
• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ -hydroxy-5a-androst-1-en-17-on) |
• |
gestrinon |
|
|
• |
1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx) |
• |
xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on) |
|
|
• |
4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on) |
• |
metenolon |
|
|
• |
5-androstenedion (xxxxxxx-5-xx-3,17-xxxx) |
• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on) |
|
|
• |
19-norandrostenediol (estr-4-en-3,17-diol) |
• |
metyltestosteron |
|
|
• |
19-norandrostenedion (xxxx-4-xx-3,17-xxxx) |
• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx (11-xxxxxxxxxxxxxxxxx, adrenosteron) |
• |
miboleron |
|
|
• |
androstanolon (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
• |
xxxxxxxxx (19-nortestosteron) |
|
|
• |
androstenediol (xxxxxxx-5-xx-3ß,17ß-xxxx) |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
• |
xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x xxxxx xxxxx s xxxxxxxx chemickou strukturou xxxx podobnými xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX ANABOLICKÉ XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX LÁTKY A XXXXXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Nespecifické xxxxx.
Xxxxxxxxxxx xxxxx x další xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) A XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1&xxxx;Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (EPO); sloučeniny xxxxxxxx xx XXX, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX-xxxxxxxxx xxxxxxxxxx a jejich xxxxxxxxxx, xxxx. CNTO-530, xxxxxxxxxxx.
X2.1.2&xxxx;Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx faktoru (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3&xxxx;Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4&xxxx;Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5&xxxx;Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, např. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ XXXXXXX
X2.2.1&xxxx;Xxxxxxx stimulující xxxxxxxxxxx x xxxx, xxxx xxxx včetně:
• choriový xxxxxxxxxxxx (XX),
• luteinizační xxxxxx (LH),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) x jeho xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx),
• xxxxxxxxxx x xxxx agonistické xxxxxxx.
X2.2.2&xxxx;Xxxxxxxxxxxxxx a jejich xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3&xxxx;Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x fragmenty, xxxx jiné včetně:
• xxxxxxx růstového xxxxxxx, xxxx. lonapegsomatropin, xxxxxxxxxxx x somatrogon,
• fragmenty xxxxxxxxx hormonu, xxxx. XXX-9604 a xXX 176-191.
X2.2.4&xxxx;Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx hormonu (XXX) x jejich xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx XX (XXXX) [např. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 a XXXX-6].
X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)
• růstový xxxxxx 1 podobný xxxxxxxx (IGF-1, mecasermin) x xxxx analogy
• xxxxxxxxxx růstové xxxxxxx (XXX)
• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)
• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)
x xxxxx růstové faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 BETA-2 XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx včetně xxxxx xxxxxxxxx izomerů jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační xxxxxxxxxx: xxxxxxxxx 1 600 xxxxxxxxxx xx 24 xxxxx v oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx jakékoliv xxxxx;
• inhalační formoterol: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů za 24 xxxxx x xxxxxxxxxx xxxxxxx, nepřekračujících 36 xxxxxxxxxx xxxxx 12 xxxxx po xxxxxxxxx dávce;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 mikrogramů xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx v moči x xxxxxxxx vyšším xxx 1 000 xx/xx nebo xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx a xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec neprokáže xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx abnormální xxxxxxxx xxx důsledkem terapeutické xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.
X4 HORMONOVÉ X METABOLICKÉ XXXXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx látky.
Látky xxxxxxxx xx xxxx X4.3 x X4.4 xxxx Nespecifické látky.
Následující xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx jsou zakázány.
S4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-androst-3-en-17-ol) |
• |
exemestan |
|
|
• |
3-androstenon (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 trion (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx xxxx včetně:
|
• |
bazedoxifen |
• |
elacestrant |
• |
raloxifen |
||
|
• |
klomifen |
• |
fulvestrant |
• |
tamoxifen |
||
|
• |
cyklofenil |
• |
ospemifen |
• |
toremifen |
S4.3. LÁTKY XXXXXXXXXXX AKTIVACI XXXXXXXXX XXXXXXXX IIB
Mimo jiné xxxxxx:
|
• |
xxxxxxxxxx neutralizující xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx xxxxxxxxx xxxxxxxx IIB, xxxx.: |
- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx receptoru xxxxxxxx IIB (např. xxxxxxxxxx) |
- xxxxxxxxxx neutralizující xxxxxxxxx xxxx xxxxxxxxxx (xxxx. apitegromab, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1
• xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), xxxx. AICAR, mitochondriální xxxxxxxx xxxxx xxxxx 12X xXXX-x (MOTS-c);
• xxxxxxxx peroxizomovými proliferáty xxxxxxxxxxxx xxxxxxxxx xxxxx (XXXXδ), např. 2-(2-methyl- 4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxx) xxxxxxxx octová (XX1516, GW501516) x;
• xxxxxxxx Xxx-xxxɑ, xxxx. XX9009, SR9011
S4.4.2 insuliny x xxxxxxxx xxxxxxxx, xxxx. S519, S597
S4.4.3 xxxxxxxxx
X4.4.4 trimetazidin
S5 XXXXXXXXX X XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx diuretika x xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. d- x x-, xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
• Xxxxxxxxx, xxxx xxxx.:
Xxxxxxxxxxxx; xxxxxxxx; bumetanid; kanrenon; xxxxxxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; indapamid; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; torasemid; xxxxxxxxxx; xxxxxxx;
• Vaptany, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;
• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x další xxxxx s xxxxxxxx xxxxxxxxx strukturou nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; xxxxxxxx; a xxxxxxx xxxxxxxxxxxxxx podávání xxxxxxxxxx xxxxxxxxxxxxxx (např. xxxxxxxxxx, brinzolamid);
• lokální xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx látky se xxxxxxxxxx xxxxxxxx limitem: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, metylefedrinu x xxxxxxxxxxxxxx xx Xxxxxx Sportovce xxxxxxxx xxxx xxxxxxxx Při Xxxxxxx xx xxxxxxx x xxxxxxxxxx nebo xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx podání xxxxxxxxxxx v xxxxxxxx xxxxxxxxx), bude xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (AAF), pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto látku xxxxx x xx, xxxxx již byla xxxxxxx xx diuretikum xxxx xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
XXXXXXXX STÁLE (XXX SOUTĚŽI X XXXX SOUTĚŽ)
Všechny zakázané xxxxxx x xxxx xxxxx jsou Xxxxxxxxxxxx x xxxxxxxx metod x X2.2, xxx xxxx Specifické xxxxxx.
X1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx množství autologní, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx nebo xxxxxxxx x červených xxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx.
XXXXXXXX
Xxxxxxxx xxxx xxxx krevních xxxxxx, včetně xxxxxxx, xxxx xxxxxxxx xxx xxxxxxxxx v xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx xxxx, xx které působí.
M1.2. Xxxxx xxxxxxxxx příjmu, xxxxxxx nebo xxxxxxx xxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx bázi xxxxxxxxxxx a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx za xxxxxx porušit xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx úprava Xxxxxx, xxxx. xxxxxxxx proteáz xx Vzorku.
M2.2. Xxxxxxxxxx xxxxxx x/xxxx injekce xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx nukleových xxxxxxx xxxx jejich xxxxxxx, které xxxxx xxxxxx sekvence xxxxxx x/xxxx exprese xxxx xxxxxxxxxx mechanismem. Xx xxxx jiné xxxxxxxx xxxxxxxxxxx úprav xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, což xxxx Xxxxxxxxxxxx látky.
Návykové xxxxx x xxxx xxxxx: xxxxxx a xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x l-, jsou xxxxxxxx.
Xxxxxxxxxxx zahrnují:
S6.A: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx (xxxxxxxxx) |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx včetně:
|
• |
2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydroxyamfetamin (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx a jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxx |
x xxxxx látky s xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx; xxxxxxxxx;
• xxxxxxxx xxxxxxxxxxx xxx xxxxxxxxxxxxxx, xxxxx, oční xxxx otické použití (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, indanazolin, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) a stimulancia xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 20255).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx jsou Specifické xxxxx.
Xxxxxxxx látky v xxxx xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, včetně xxxxxx xxxxxxxxxx všech xxxxxxxxx xxxxxxx, např. x- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx a xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (heroin) |
• |
metadon |
• |
oxykodon |
• |
tramadol |
|||
|
• |
oxymorfon |
S8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (THC)
Všechny xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx jsou xxxxxxxx, xxxx.
• x xxxxxx (xxxxx, marihuana) x xxxxxxxxx xxxxxxxxxx
• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxx (XXX)
• syntetické kanabinoidy xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX PŘI XXXXXXX
Xxxxxxx zakázané látky x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx jsou podávány xxxxxxxxxx injekční, xxxxxxxxx [xxxxxx oromukózní (xxxx. xxxxxxx, gingivální, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx xxxx včetně:
|
• |
beklometazon |
• |
dexametazon |
• |
mometazon |
||
|
• |
betametazon |
• |
flunisolid |
• |
prednizolon |
||
|
• |
budesonid |
• |
fluokortolon |
• |
prednizon |
||
|
• |
ciklesonid |
• |
flutikason |
• |
triamcinolon xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx způsoby xxxxxx (xxxxxx inhalačního x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, pokud xx xxxxxxxxx v xxxxx xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX V URČITÝCH XXXXXXXX
Xxxxxxx zakázané látky x této třídě xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x následujících xxxxxxxx Xxx Xxxxxxx x xxx je xx xxxxxxxx symbolem (*) x Xxxx soutěž.
|
• |
lukostřelba (XX)* |
• |
Xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx |
|
|
• |
xxxxxxxxxxxx sport (FIA) |
|||
|
• |
billiard (xxxxxxx xxxxxxxxxx) (WCBS) |
|||
|
• |
šipky (XXX) |
|||
|
• |
xxxx (IGF) |
|||
|
• |
minigolf (WMF) |
|||
|
• |
střelba (XXXX, IPC)* |
* xxxxxxxx xxxx Mimo xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
1) katin (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 ml.
3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx v xxxx xxxxx než 10 xxxxxxxxxx v 1 ml.
4) xxxxxxxxx (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx anestetiky.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: tyto xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2025 x nejsou považovány xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 163/2026 Xx. xxxxx xxxxxxxxx dnem 15.9.2026.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních předpisů x odkazech xxxx xxxxxxxxxxxxx, pokud xx xxxx xxxxxx xxxxxxxxx xxxxx shora uvedeného xxxxxxxx předpisu.